The CXCL13 index (ICXCL13), was identified as a potential biomarker of intrathecal production of CXCL13 to predict future disease activity in MS patients 2 years after presenting with the clinically isolated syndrome (CIS) (Pike et al., 2023). This evidence concerns the gene CXCL13 and in situ carcinoma.